Intercure Ltd. (INCR)
NASDAQ
Key stats Fiscal year 2024
Income statement
- Revenue
- 238,845,000 -32.8%
- Net income
- -67,795,000
- Gross profit
- 30,233,000
- Operating income
- -67,208,000
- Earnings per share
- -1.48
- R&D expense
- 414,000
Growth and profitability
- Gross margin
- 12.66
- Operating margin
- -28.14
- Net margin
- -28.38
- Return on equity
- -17.08
- Return on assets
- -8.89
- Free cash flow margin
- -29.85
Balance sheet
- Total assets
- 762,574,000
- Total liabilities
- 364,903,000
- Shareholders' equity
- 396,969,000
- Cash and equivalents
- 78,318,000
- Debt
- 183,000,000
- Net debt
- 104,682,000
- Current ratio
- 1.73
- Debt to equity
- 0.46
Cash flow and ratios
- Operating cash flow
- -66,926,000
- Free cash flow
- -71,302,000
Shareholder returns
- Shares outstanding
- 54,681,335
- Book value per share
- 7.26
Company information
- Headquarters
- Herzliya, L3
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Intercure Ltd. trades on NASDAQ under the ticker symbol INCR. This page brings together its price chart, company profile, key financial figures and technical indicators.